Erik Greb joined the staff of Neurology Reviews in January 2012. Since then, he has attended scientific conferences, conducted video interviews, and written about clinical research in multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, stroke, and other neurologic disorders. In addition to news articles, Erik has written investigative stories about multiple sclerosis, headache, and epilepsy. He previously wrote about pharmaceutical manufacturing, drug formulation and delivery, quality assurance, and regulation for Pharmaceutical Technology.
News
Treatment for hepatitis C reduces risk of Parkinson’s disease
Data support the hypothesis that hepatitis C virus infection is a risk factor for incident Parkinson’s disease.
News
Stewart Tepper: Emgality approval ‘very exciting’
The treatment binds to calcitonin gene-related peptide and is the first therapy to reduce the frequency of episodic cluster headache attacks.
News
Switching from interferon beta-1a to alemtuzumab improves MS outcomes
SEATTLE – The switch is associated with a high rate of freedom from relapse and a reduced rate of brain volume loss...
News
High-efficacy DMTs may reduce depressive symptoms in MS
SEATTLE – Higher-efficacy DMTs may have antidepressive properties, possibly because of their anti-inflammatory...
News
Patients with MS who consider using marijuana are more likely to engage in risky behaviors
SEATTLE – Discussions of marijuana use should include discussions of health behaviors.
News
Fingolimod reduces MS disease activity, compared with glatiramer acetate
SEATTLE – In patients with relapsing multiple sclerosis, 0.5 mg/day fingolimod reduces the annualized relapse rate...
News
Adherence to oral treatments for MS is poor
SEATTLE – One in three patients with MS has a lapse in oral therapy that lasts for at least 30 days, and...
News
Extended-release arbaclofen reduces MS-related spasticity
SEATTLE – A regimen of twice-daily, extended-release arbaclofen could reduce the adverse events associated with...
News
Periodic limb movements during sleep are common in patients with MS and fatigue
SEATTLE – Sleep apnea may not be the only comorbidity that causes fatigue in multiple sclerosis, and treating...
News
Alemtuzumab provides greater reductions in serum NfL than interferon beta-1a
Seattle – The results are consistent with alemtuzumab’s superior efficacy, compared with interferon beta-1a, but the...
News
Age may influence choice of behavioral therapy to improve sleep in MS
SEATTLE – Few studies have examined the relationships between physical activity, sedentary behavior, and sleep...
News
Anxiety and fatigue impair processing speed in MS
SEATTLE – When cognitive fatigue increases in patients with MS, increased anxiety is associated with slower...
News
MS significantly affects employment and home activities
SEATTLE – Although most people with MS are employed, approximately 28% are underemployed or unemployed, according to...
News
Alemtuzumab increases the likelihood of disability improvement in MS
SEATTLE – Disability improvements often involve multiple functional systems, regardless of baseline disability.
News
Inebilizumab reduces the risk of NMOSD attacks
Philadelphia – The humanized monoclonal antibody was well tolerated and reduced the risk of disability worsening.